Schizophrenia Research
Volume 93, Issue 1 , Pages 51-57 , July 2007

CNS 14-3-3ζ: Changes with sex but not psychiatric diagnoses or psychotropic drug treatment

  • Brian Dean

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The University of Melbourne Department of Psychiatry, Parkville, Australia
    • The University of Melbourne Department of Pathology, Parkville, Australia
    • The Department of Psychological Medicine, Monash University, Clayton, Victoria, Australia
    • Corresponding Author InformationCorresponding author. NHMRC Senior Research Fellow and Head, The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria 3052, Australia. Tel.: +61 3 9389 2940; fax: +61 3 9387 5061.
    • ,
  • Simone A. Boer

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The University of Melbourne Department of Clinical and Biomedical Sciences, Geelong, Australia
    • ,
  • Andrew Mackinnon

      Affiliations

    • Centre for Mental Health Research, Australian National University, Canberra, ACT, Australia
    • ,
  • Michael Berk

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The University of Melbourne Department of Clinical and Biomedical Sciences, Geelong, Australia

Received 2 October 2006 ,Revised 18 February 2007 ,Accepted 27 February 2007.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4 edn.. Washington, D.C.: American Psychiatric Association; 1994;
  2. Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat. Rev., Neurosci. 2003;4:752–762
  3. Coblitz B, Wu M, Shikano S, Li M. C-terminal binding: an expanded repertoire and function of 14-3-3 proteins. FEBS Lett. 2006;580:1531–1535
  4. Fountoulakis M, Hardmeier R, Hoger H, Lubec G. Postmortem changes in the level of brain proteins. Exp. Neurol. 2001;167:86–94
  5. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 2000;40:617–647
  6. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch. Gen. Psychiatry. 2004;61:310–317
  7. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Mackinnon A, et al. Problem of diagnosis in postmortem brain studies of schizophrenia. Am. J. Psychiatry. 1996;153:533–537
  8. Ikeda K, Inoue S. Estrogen receptors and their downstream targets in cancer. Arch. Histol. Cytol. 2004;67:435–442
  9. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, et al. Tissue pH as an Indicator of mRNA Preservation in Human. 1995;
  10. Middleton FA, Peng L, Lewis DA, Levitt P, Mirnics K. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology. 2005;30:974–983
  11. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 2000;44:151–155
  12. Wong AH, Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, et al. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr. Res. 2005;78:137–146
  13. Zanusso G, Fiorini M, Farinazzo A, Gelati M, Benedetti MD, Ferrari S, et al. Phosphorylated 14-3-3zeta protein in the CSF of neuroleptic-treated patients. Neurology. 2005;64:1618–1620

PII: S0920-9964(07)00114-4

doi: 10.1016/j.schres.2007.02.022

Schizophrenia Research
Volume 93, Issue 1 , Pages 51-57 , July 2007

Article Tools

* Image Usage & Resolution